(Q44085925)

29 November 2017

title

Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis (English)

1 reference

29 November 2017

main subject

Clostridium difficile

0 references

author name string

Richard M Cadle

1

1 reference

29 November 2017

Mohammad D Mansouri

2

1 reference

29 November 2017

Nancy Logan

3

1 reference

29 November 2017

Denise R Kudva

4

1 reference

29 November 2017

Daniel M Musher

5

1 reference

29 November 2017

publication date

1 November 2007

1 reference

American Journal of Health-System Pharmacy

29 November 2017

published in

1 reference

29 November 2017

volume

64

1 reference

29 November 2017

issue

22

1 reference

29 November 2017

page(s)

2359-2363

1 reference

An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Treatment of Clostridium difficile colitis and diarrhea with vancomycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Treatment of antibiotic-associated pseudomembranous colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Occurrence and significance of gastric colonization during acid-inhibitory therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Nitazoxanide for the treatment of Clostridium difficile colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060629

31 March 2020

Identifiers

DOI

10.2146/AJHP060629

1 reference

release_hztnetqjt5aadjwtjvjniaif2i

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hztnetqjt5aadjwtjvjniaif2i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference